NovaBay Pharmaceuticals (NBY) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $398000.0.
- NovaBay Pharmaceuticals' Accumulated Depreciation & Amortization fell 4164.22% to $398000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $398000.0, marking a year-over-year decrease of 4164.22%. This contributed to the annual value of $674000.0 for FY2024, which is 122156.86% up from last year.
- Latest data reveals that NovaBay Pharmaceuticals reported Accumulated Depreciation & Amortization of $398000.0 as of Q3 2025, which was down 4164.22% from $570000.0 recorded in Q2 2025.
- In the past 5 years, NovaBay Pharmaceuticals' Accumulated Depreciation & Amortization registered a high of $729000.0 during Q3 2022, and its lowest value of $51000.0 during Q4 2023.
- In the last 5 years, NovaBay Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $641000.0 in 2021 and averaged $574052.6.
- As far as peak fluctuations go, NovaBay Pharmaceuticals' Accumulated Depreciation & Amortization soared by 434285.71% in 2021, and later crashed by 8127.93% in 2022.
- Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Accumulated Depreciation & Amortization stood at $641000.0 in 2021, then plummeted by 81.28% to $120000.0 in 2022, then tumbled by 57.5% to $51000.0 in 2023, then surged by 1221.57% to $674000.0 in 2024, then plummeted by 40.95% to $398000.0 in 2025.
- Its Accumulated Depreciation & Amortization was $398000.0 in Q3 2025, compared to $570000.0 in Q2 2025 and $569000.0 in Q1 2025.